Spanish drugmaker Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols, which makes drugs using blood plasma, plans to float a minority stake in the biopharma business. The parent company will maintain its listing in Spain and retain majority ownership of the U.S. business.
Sign up here.
“The transaction rei… [716 chars]
Source: Reuters | Published: 2026-03-24T21:11:44Z
Credit: Reuters
